Alto Neuroscience
Precision medicine for the brain is here.
Precision medicine for the brain is here.
Alto Neuroscience is revolutionizing psychiatry with its slogan "Precision medicine for the brain is here." Founded in 2019 in the United States, the company is dedicated to leveraging individuals' neurobiology to develop personalized and highly effective medicines, expediting patients' recovery.
Alto's Precision Psychiatry Platform™ utilizes biomarkers such as EEG and wearable data, behavioral patterns, genetics, and other factors to match patients with tailored treatment. By incorporating AI-derived brain biomarkers, the company is reshaping the field of psychiatry, crucially needed in today's world. Alto Neuroscience's recent $45.00M Series C funding on 21 November 2023 saw participation from a consortium of notable investors including Franklin Templeton, Windham Venture Partners, Alexandria Venture Investments, Alkeon Capital, Eli Lilly, Lightswitch Capital, Point 72 Ventures, Whatif Ventures, InVivium Capital, and Alpha Wave Ventures.
Alto Neuroscience's innovative approach and significant financial backing position the company as a prominent player in the Biopharma and Biotechnology industries, offering promising prospects for both patients and investors.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $45.00M | 10 |
|
21 Nov 2023 |
| Series B | $25.00M | 2 |
|
30 Jan 2023 |
| Debt Financing | $35.00M | 1 |
|
30 Jan 2023 |
| Series B | $35.00M | 10 |
|
25 Oct 2022 |
| Venture Round | $59.26M | - | 06 Apr 2022 |
No recent news or press coverage available for Alto Neuroscience.
We care about your data, and we'd love to use cookies make your experience better.
